A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

(BE HEARD I)

ID# NCT04242446

Recruitment Status: recruiting as of August 2020.

 

Estimated Completion Date: May 2023

Sponsors and Collaborators: UCB Biopharma SRL

Locations: multiple locations please refer to link above for further information.

Contact: UCB Cares 1844599 ext 2273 

UCBCares@ucb.com

Get Updates

Affiliated With

  • Instagram
  • Twitter
  • Facebook Social Icon
  • Pinterest

© 2020 by HS Connect   |  HSConnect.org@gmail.com  |  Hidradenitis Suppurativa Online

PO Box 73244 Puyallup, WA 98373  |  253.256.1579